Should we rename low-risk (‘indolent’) cancers in a bid to reduce anxiety and harm from unnecessary investigation and treatment?
Should we rename low-risk (‘indolent’) cancers in a bid to reduce anxiety and harm from unnecessary investigation and treatment?